Merck & Co Inc
Latest Merck & Co Inc News and Updates
Merck Sells COVID Pill to U.S. at $700 Per Treatment Course
Why 2021 Could Be a Very Healthy Year for Merck Stock
Study Shows Merck Antiviral Drug Is Effective in Treating COVID-19
How Did AstraZeneca’s CVMD Franchise Perform in 2014?
In 2014, AstraZeneca’s CVMD franchise generated nearly $9.8 billion, a 11% rise in sales as compared to $8.8 billion in 2013.
Merck & Co.’s Animal Health Segment
The revenues of Merck & Co.’s Animal Health segment have improved due to increased sales in the Companion Animal Products segment.
Wall Street Analysts Are Mostly Positive on Merck in September
Of the 19 analysts tracking Merck (MRK) stock in September, four recommended a “strong buy” while ten analysts recommended a “buy.”
Merck Expects Modest Revenue Growth in Fiscal 2016
Merck provided revenue guidance of $39.7 billion–$40.2 billion in 2016. It expects negative foreign exchange fluctuations to reduce its fiscal 2016 revenue.
Is Novo Nordisk Trading at a Discount or Premium?
For the last five years, Novo Nordisk (NVO) has been trading at higher multiples when compared with peers.
A Look at Johnson & Johnson’s Post-2Q17 Valuation
Headquartered in New Jersey, Johnson & Johnson (JNJ) is one of the largest pharmaceutical companies, with its products sold in over 200 countries worldwide. This series will look at how it has performed since its 2Q17 earnings announcement.
What Are Analysts’ Recommendations for Merck in 2017?
For 2016, Merck & Co. (MRK) reported revenue close to $39.8 billion, a year-over-year (or YoY) rise of ~1%. New product launches have played major roles in boosting Merck’s 2016 revenue.
Johnson & Johnson’s Valuation Cheat Sheet
On January 26, 2017, the company was trading at a forward PE of ~15.8x. Based on the last five years’ multiple range, JNJ’s current valuation is neither high nor low.
Sanofi Increased Net Revenues in 2014
Sanofi’s net revenues increased by ~2.5% to 33.8 billion euros in 2014, as compared to $23.2 billion in 2013.
What Analysts Think about Bristol-Myers Squibb
Of 28 analysts covering BMY’s stock, 42.3% gave it a “buy” recommendation, while 50.0% gave it a “hold” recommendation. Only 7.7% rated it as a “sell.”
Analysts’ Expectations for Sanofi
According to a March 3, 2016, Bloomberg consensus of five brokerage firms, 60% of brokerage firms rated Sanofi as a “buy,” while 40% of the broker firms rated the company as a “hold.”
Celgene’s Revlimid Expected to Post Strong Revenue in 2017
According to unaudited financial results published by Celgene (CELG) on January 9, 2017, Revlimid sales for 2016 are about $7.0 billion, a YoY rise of about 20.0%.
Novartis’s Adjusted Earnings per Share Declined 7% in 2Q15
Novartis (NVS) posted its 2Q15 earnings on July 21, 2015. The company achieved adjusted EPS of $1.27 for 2Q15, ~7% lower than in 2Q14.
What Analysts Project for Eli Lilly in 3Q17
For 3Q17, analysts estimate that Eli Lilly will post EPS of $1.03 on revenues of $5.5 billion.
How Did Pfizer Perform in 3Q17?
In 3Q17, Pfizer (PFE) generated revenues of $13.2 billion, an increase of ~1% on a year-over-year (or YoY) basis and a 1% increase on a quarter-over-quarter basis.
Analysts’ Recommendations for Merck & Co. after 4Q17
Merck & Co. (MRK) missed Wall Street analysts’ estimates for revenues but surpassed analysts’ estimates earnings per share.
Inside XLV’s Large Caps: Pfizer’s 1Q16 Earnings
Pfizer recently rose by 2.7% on revenues of $13 billion for 1Q16, as compared to $10.9 billion in 1Q15, which represents a growth of 20% YoY.
What Did AGN’s US Medical Aesthetics Segment Contribute in 1Q16?
Allergan’s US medical aesthetics segment includes facial aesthetics, medical dermatology products, and a wide range of silicone and saline breast implants.
Merck’s Valuation Cheat Sheet for Fiscal 1Q16
Merck & Co.’s (MRK) current valuation is neither high nor low. Its valuation multiple has followed the industry’s overall trend over the last five years.
Market Response to EMA Validation of Opdivo Application
BMY has four key oncology products, including Erbitux, Opdivo, Sprycel, and Yervoy. Two of these contributed more than $1 billion in 2014.
Label Expansion Expected to Boost Keytruda’s 2017 Revenue
On October 24, 2016, the FDA approved Merck & Co’s (MRK) Keytruda as a second-line therapy for patients suffering from non-small cell lung cancer (or NSCLC).
Pfizer Missed Analysts’ Third-Quarter Revenue Estimates
Pfizer (PFE) released its third-quarter earnings on October 30.
Understanding the Revenue Fall in AstraZeneca’s Largest Segment in 3Q16
AstraZeneca’s (AZN) CVMD (Cardiovascular and Metabolic Disease) segment contributed nearly 32.4% of total company revenues in 3Q16.
Bristol-Myer Squibb’s Opdivo Is Keytruda’s Strong Competitor
the U.S. Food and Drug Administration accepted the filing of a supplemental Biologics License Application for Bristol-Myers Squibb’s Opdivo.
What Could Expand Keytruda’s Revenues?
In addition to the US market, Merck’s (MRK) Keytruda has been approved in more than 50 international markets for metastatic melanoma.
Merck’s Gardasil and What It Could Mean
Total sales from Merck’s Gardasil during 3Q16 reached $860 million, a rise of ~38% over the $625 million in 3Q15.
Assessing Novartis’s Performance in October So Far
Novartis’s ADR (American depositary receipt) has fallen ~1.0% to date in October, while it’s risen nearly 3.3% in the last month.
Venclexta Witnessed Healthy Demand Trends in 1Q17
AbbVie’s (ABBV) Venclexta was approved by the FDA on April 11, 2016. AbbVie has also successfully launched Venclexta in Germany and France.
Inside Celgene’s Revlimid: Strong Patient Demand in 4Q16
After the approval of the drug as a therapy for newly diagnosed multiple myeloma, Celgene’s Revlimid has witnessed rapid growth in market share worldwide.
Novartis on the Street: Analysts’ Recommendations in November
Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold.”
What Are Biosimilars and Why Do They Benefit Generic Pharma?
BUTCHER: Going back to what you said about generics being a cheaper alternative, why are they cheaper? DUFFY: The barriers to generic markets are usually a lot lower. If we look at the United States, back in 1984 they passed the Hatch-Waxman Act and essentially what this did was allow for an expedited approval process […]
Exploring Novavax’s Vaccine Candidates for RSV
According to Novavax, ~64.0 million RSV infections occur every year on a global basis. The global cost of RSV exceeds $88.0 billion.
AbbVie’s Viekira Pak Saw Weaker-than-Expected Performance
Viekira Pak managed to earn revenues worth about $414 million in 1Q16. The drug’s sales in the US market, however, fell YoY (year-over-year) by about 9.3% and reached $125 million in 1Q16.
What’s the Story behind the Pfizer-Medivation Deal?
Medivation’s portfolio complements Pfizer’s existing oncology portfolio that includes solid tumors, hematology, and immunology-oncology.
Why Incyte Stock Fell ~9% on April 24
On April 24, Incyte (INCY) stock fell ~9% on news regarding its drug Baricitinib, which is under FDA review.
AstraZeneca and Its Oncology Segment’s Growth in 2Q16
AstraZeneca’s (AZN) oncology segment is another key focus area. The segment’s contribution increased to more than 15% in 2Q16.
Johnson & Johnson’s 3Q15 Changes in Growth Rate
Foreign exchange rates seem to have had a negative impact on Johnson & Johnson’s growth rate since ~50% of total revenues are reported from sales outside the US.
What to Expect from Pfizer’s 2Q16 Earnings
In Pfizer’s 2Q16 results, analysts expect to see EPS (or earnings-per-share) of $0.62 and revenues of ~$13.0 billion for 2Q16. The company has surpassed Wall Street analysts’ estimates for EPS over the last few quarters.
Merck and AstraZeneca Announced EMA Approval for Lynparza
Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.
How Merck’s Oncology Drugs Emend and Temodar Could Perform in 2017
In 2016, Merck’s (MRK) Emend reported revenues of around $549 million, which reflected 3% year-over-year growth.
What’s behind Biogen Buyout Rumors?
Since early August 2016, there have been rumors of a likely buyout of Biogen (BIIB) by one of the many interested suitors in the biotechnology industry.
Amgen: Exploring Opportunities in the Bone Segment
Amgen’s Prolia is the leading brand for treating postmenopausal osteoporosis, or PMO, in women with a high risk of bone fracture.
AbbVie Hopes to Commercialize Next-Generation HCV Regimen by 2017
AbbVie (ABBV) plans to complete its Phase 3 registrational program for investigational next-generation Hepatitis C virus (or HCV) therapy by 2016.
Why AstraZeneca’s oncology pipeline is attractive to Pfizer
Pfizer (PFE) is seeking to expand its oncology franchise and a combination with AstraZeneca (AZN) would be meaningful due to the latter’s pipeline of cancer drugs.
Key Factors That Impact Johnson & Johnson’s Forward Valuation
Two factors expected to impact Johnson & Johnson’s forward valuation are increasing competition for Olysio and further decline in international revenues.
How GlaxoSmithKline Stock Performed in 1Q18
GlaxoSmithKline stock has risen ~6.4% in 1Q18, while its stock has risen ~12.6% YTD (year-to-date) as of April 6, 2018.
Eli Lilly’s Valuation on May 17
On May 17, Eli Lilly was trading at a forward PE multiple of 15.2x, which compares to the industry average of 13.6x.
GlaxoSmithKline Increases Top Line in 2Q16
GlaxoSmithKline (GSK) reported a 10.9% increase in its top line in its 2Q16 earnings on July 27, 2016. It met Wall Street analysts’ estimates for revenues and EPS.
Analyzing Johnson & Johnson’s 1Q18 Profitability
Johnson & Johnson (JNJ) reported revenues of $20.0 billion during 1Q18, 12.6% growth as compared to revenues of $17.8 billion during 1Q17.
European Medicines Agency Validates Merck’s Keytruda Combo
Merck’s (MRK) Keytruda (pembrolizumab) is approved to treat various forms of cancer.
Johnson & Johnson Gets FDA Approval for Type 2 Diabetes Drug
On September 21, 2016, the FDA approved Jannsen Pharmaceuticals’ Invokamet XR for the treatment of adults suffering from Type 2 diabetes.
What Are Generic Drugs and Why Are They Important?
TOM BUTCHER: What are generic drugs, and why are they important? JAMES DUFFY: Generic drugs are drugs that are comparable to their brand-name counterparts. They are comparable in terms of the dosage, effectiveness, and intended use. Generics are important because they are essentially a less-expensive alternative to their brand-name counterparts. This, of course, is expected […]
What Were Pfizer’s Major Achievements in 2016?
During 2016, Pfizer (PFE) succeeded in expanding its label for Ibrance, its breast cancer treatment.
Novartis Will Report Its 4Q15 Earnings on January 27
Novartis is set to release its 4Q15 and full-year 2015 earnings on January 27, 2016. Analysts estimate an EPS of $1.32 for 4Q15.
Januvia and Janument: An Update on Merck’s Diabetes Franchise after 2Q17
In 2Q17, Merck’s (MRK) Januvia generated revenues of around $948 million, which reflected an ~11% decline on a year-over-year basis and 13% growth on a quarter-over-quarter basis.
Sales Performance Analysis of Roche’s Pharmaceuticals Division
Roche Holding (RHHBY) generated ~78% of its group sales from the pharmaceuticals division.
Durvalumab and Tagrisso May Boost AstraZeneca’s Revenues in 2017
On December 9, 2016, the FDA accepted for review its first-ever biologics license application (or BLA) submitted by AstraZeneca (AZN).
Pfizer Has Strong Track Record since 2010
As of November 1, Pfizer had ~94 projects in various development stages. More than 40% of these projects are in phase three or the registration phase.
Novartis Focuses on Portfolio Prioritization to Boost Profitability
To ensure long-term relevance as well as quick adaptability to changing market needs, Novartis (NVS) is focusing on five major initiatives in 2017.
Opdivo Is a Key Growth Driver for Bristol-Myers Squibb in 2016
On November 10, 2016, the FDA approved Opdivo as a treatment option for patients suffering with recurring or metastatic squamous cell carcinoma of the head and neck (or SCCHN).
Biogen’s Interferon Therapies Could Witness Modest Fall in 2017
In 2016, Biogen’s (BIIB) interferon therapies, Avonex and Plegridy, together reported revenues of around $2.8 billion, which reflected a drop of ~6% on a year-over-year (or YoY) basis.
Sanofi Misses Wall Street Estimates for 1Q18 Revenues
Sanofi (SNY) missed Wall Street analysts’ estimates for revenues today but beat estimates for earnings per share.
What Were the Overall Trends in Large-Cap Mutual Funds Last Year?
Most of the large-cap mutual funds have the information technology sector as their top choice.
AbbVie Strengthens Its Position in the Virology Segment
In addition to Humira, AbbVie also offers several virology drugs targeting diseases such as hepatitis C, HIV, and respiratory syncytial virus.
What to Expect from Johnson & Johnson’s 4Q15 Earnings
Johnson & Johnson has returned nearly 1.2% year-to-date while Sanofi, Merck, and Novartis have returned ~0.5%, -4.4%, and -3.5%, respectively.
What Will Be a Key Driver of Biogen’s Future Valuations?
Biogen’s investigational Alzheimer’s disease drug, aducanumab, is one of the four therapies accepted in the EMA’s Priority Medicines program (or PRIME).
Medicaid Restrictions Are Affecting Gilead’s Hepatitis C Drug Sales
Since the launch of Sovaldi in late 2013, Gilead Sciences has managed to treat about 1,000,000 hepatitis C (or HCV) patients globally.
AstraZeneca May Witness a Fall in 2017 Net Profit Margin
Wall Street analysts have projected AstraZeneca’s (AZN) 2017 net profit margins at about 12.2%, which is lower by 300 basis points on a YoY basis.
Other Drugs for Non-small Cell Lung Cancer
Approximately 85% of all lung cancers in the United States are non-small cell lung cancers, and 10% to 15% of these are EGFR mutation-positive.
Tagrisso Expected to Be a Key Growth Driver for AstraZeneca in 2017
Launched in Japan in 2Q16, AstraZeneca’s (AZN) 1Q17 revenues for Tagrisso approached $39 million in this major emerging market.
A Look into Merck’s Immunology and Oncology Portfolio
In 1H17, Remicade generated revenues of around $437 million, which is a 37% decline year-over-year.
Merck’s Relebactam Met Primary Endpoints in Phase 3 Study
Merck’s Relebactam is an investigational drug for the treatment of certain forms of imipenem-non-susceptible bacterial infections.
FDA Granted Breakthrough Therapy Status to Merck’s HCV Therapy
The U.S. Food and Drug Administration (or FDA) granted breakthrough therapy designation to Merck’s (MRK) grazoprevir/elbasvir (100mg/50mg) combination therapy.
Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates
Bristol-Myers Squibb beat Wall Street analysts’ estimates for earnings per share and revenues in 1Q18.
Teva’s Respiratory Drugs Contribute 11% to Specialty Medicines
Teva’s respiratory drugs franchise provides solutions for asthma, COPD, and allergic rhinitis. Respiratory drugs contributed nearly 11% of total revenues for Teva’s Specialty Medicines in 2014.
In high spirits? Why did Tudor open position in Beam?
Paul Tudor Jones II in 1982 founded Tudor Investment Corporation, which is today a leading asset management firm headquartered in Greenwich, Connecticut. The Tudor Group, consisting of Tudor Investment Corporation and its affiliates, is involved in active trading, investing and research in assets across fixed income, currencies, equities and commodities asset classes and related derivative […]
Understanding the Performance of Merck’s Hospital Acute Care Drugs Noxafil and Cubicin
In 4Q17, Merck’s (MRK) Cubicin reported revenues of $92 million, which was ~23% lower on a YoY (year-over-year) basis.
Xtandi’s Prescription Volumes Continue to Rise in 2017
In this series, we’ll look at Pfizer’s main revenue drivers in 2017, and what could steer its performance in 2018.
Johnson & Johnson’s Q2 2018 Earnings Estimates
As per Wall Street analysts estimates, Johnson & Johnson (JNJ) is expected to report adjusted EPS (earnings per share) of $2.07 in the second quarter of fiscal 2018.
Pfizer Reports 1Q18 Earnings and Revenue Growth
Pfizer (PFE) released its 1Q18 earnings today, reporting another strong quarter for the Innovative health business.
Pfizer Has Received Commercial Rights for Cresemba in Europe
On June 14, 2017, Pfizer (PFE) announced an agreement with Basilea Pharmaceutica for exclusive commercial rights for Cresemba in Europe.
Ligand Pharmaceuticals’s Portfolio Pyramid as Its Valuation Catalyst
Ligand Pharmaceuticals’s (LGND) product portfolio has expanded from nine programs in 2008 to 140+ programs in 2016.
Analysts Cut Target Prices on MYL Stock after Its Q2 2018 Results
Mylan (MYL) reported its Q2 earnings on August 8. On August 13, 13 of 20 surveyed firms still held a “buy” or “strong buy” rating on MYL.
Understanding Johnson & Johnson’s Ownership Structure
As of January 2015, Johnson & Johnson’s ownership structure is dominated by passive investments. They account for more than 80% of the total ownership structure.
Pfizer’s Valuation as of May 22
Pfizer trades at a forward enterprise-value-to-EBITDA multiple of 10.3x, which is much lower than the industry average of 11.6x.
AbbVie’s Rova-T and the Treatment of Small Cell Lung Cancer
AbbVie (ABBV) expects to secure FDA (U.S. Food & Drug Administration) approval in the third-line plus small cell lung cancer (or SCLC) indication in 2018.
Expert Q&A: What to Know Before Investing in Generic Pharma? (Part 2)
(continued from Part 1) 4. What is the nature of the cash flows for generics companies? Stable, driven by a constant demand for prescription drugs? Or lumpy, driven by growth from drugs coming off patent? The larger companies in this sector tend to have stable, steadier cash flows due to established lineups of approved products. […]
Analysts Recommendations for AbbVie in August 2017
Twenty-one analysts were tracking AbbVie in August 2017. Three analysts suggested a “strong buy,” while seven suggested a “buy.”
How Merck Is Expected to Perform in 2017
In 1Q17, Merck (MRK) generated revenues of ~$9.4 billion, which reflected 1% YoY growth. Merck expects its GAAP net revenues in fiscal 2017 to reach $39.1 billion–$40.3 billion.
How’s Gilead Sciences Expected to Perform in 2016?
Gilead Sciences lowered its guidance for fiscal 2016 due to weak 2Q16 results reported on July 25. It expects its 2016 revenues to be $29.5 billion–$30.5 billion.
Inside Novartis’s Eye Care Performance in 4Q16
Alcon, NVS’s eye care segment, saw its 4Q16 revenues fall ~2% to ~$1.4 billion, including no change in sales but a -2% impact from foreign exchange.
How Eli Lilly’s Cardiovascular Products Have Been Faring
Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes cardiovascular products such as Cialis, Effient, and other products.
How Pfizer’s Vaccine Franchise Is Positioned in 2017
In 2016, Pfizer’s (PFE) Prevnar 13 reported revenues of ~$5.7 billion, which reflected a ~8% decline on a YoY (year-over-year) basis.
These Pharma Stocks Offer the Most Upside Potential
In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.
Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class
The PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1) class consists of Bristol-Myers Squibb’s Opdivo, Merck’s Keytruda, and Roche’s Tecentriq.
Johnson & Johnson’s Profitability Improves in 2Q15
Johnson & Johnson’s net profit margin improved to 25.4% for 2Q15 compared to 22.2% for 2Q14 due to the divestiture of some low profitability products and improved sales of high profitability products.
What Drove Gilead Sciences’ Hepatitis C Portfolio in 3Q15?
Gilead Sciences’ (GILD) hepatitis C (or HCV) portfolio is expected to continue driving the company’s revenues and net profit margins in 3Q15.